MedTrace Logo

Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI

NCT03023566 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2022-05-20

No results posted yet for this study

Summary

The goal of this study is to evaluate safety and efficacy of Dotarem enhanced MRI in pediatric and neonatal population who are referred for contrast enhanced MRI at Phoenix Children's Hospital.

Conditions

  • Brain Diseases

Interventions

DRUG

Dotarem

Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)

Sponsors & Collaborators

  • Guerbet

    collaborator INDUSTRY

  • Phoenix Children's Hospital

    lead OTHER

Principal Investigators

  • Jeffrey H Miller, MD · Phoenix Children's Hospital

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-09
Primary Completion
2017-11-12
Completion
2017-11-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023566 on ClinicalTrials.gov